Linked Life Data

9809902

Source:http://linkedlifedata.com/resource/pubmed/id/9809902

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8A
pubmed:dateCreated
1998-11-20
pubmed:abstractText
This review summarizes the results of placebo-controlled trials of propafenone, a class IC antiarrhythmic drug, in patients with supraventricular tachycardia, atrial fibrillation (AF), and atrial flutter. Success rates for cardioversion from AF or flutter to sinus rhythm of 9-93% have been obtained with intravenous propafenone. The duration of arrhythmia is an important factor in the degree of success. The use of a single oral dose has also been reported to be effective in a number of studies. Several placebo-controlled studies have confirmed the effectiveness of propafenone in the long-term suppression of both suproventricular tachycardia and AF and flutter. These reported trials have shown consistent benefit with propafenone compared with placebo in preventing arrhythmia recurrence. The adverse side effect profile for propafenone has also been reviewed with particular reference to the potential for proarrhythmia. The rate of side effects is dose-dependent and tends to be higher in patients with underlying structural heart disease. Overall propafenone has been shown to be an effective antiarrhythmic drug with an acceptable side effect profile for the acute and long-term treatment of supraventricular arrhythmias.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0002-9149
pubmed:author
pubmed:issnType
Print
pubmed:day
16
pubmed:volume
82
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
59N-65N
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1998
pubmed:articleTitle
Placebo-controlled evaluations of propafenone for atrial tachyarrhythmias.
pubmed:affiliation
Glasgow Royal Infirmary, Scotland, United Kingdom.
pubmed:publicationType
Journal Article, Review